Chart: FDA Advisory Committee Votes On Acetaminophen Restrictions
This article was originally published in The Tan Sheet
You may also be interested in...
OTC Tylenol Sales Could Shrink By Half With Acetaminophen Dose Restriction
Johnson & Johnson could lose roughly $500 million in nonprescription Tylenol sales if FDA follows an advisory committee recommendation to switch 500-g tablets of acetaminophen to Rx status
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands